Market Timing with TurnerTrends Provides Great Stock Picks for the Sophisticated Investor   Timing the Market well requires Stock Picks that work
Home Subscribe! StockMasterPro ETFMasterPro CycleProphet Partners Members
Top 100 Stocks | Search Stocks | Sector Analyzer | Industry Analyzer
New Hot Stock Picks | How we Rate Stocks | Tutorial
My Stock Watch Lists: Add+
Ticker: 

TurnerTrends Stock Rating Report for VNDA

Data valid for week beginning March 08, 2010

Ticker Company Name
VNDA   [News] Vanda Pharmaceuticals Inc
Company Profile
"Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with worldwide commercial rights to two product candidates in clinical development. The Company’s product portfolio includes Iloperidone, a compound for the treatment of schizophrenia and Tasimelteon, a compound for the treatment of sleep and mood disorders, including circadian rhythm sleep disorders (CRSD)."

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Technical Chart (3 year) Sector Chart Industry Chart

VNDA Technical Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for VNDA. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for Vanda Pharmaceuticals Inc next week. Sign up today and start making money!

FREE TRIAL!!


Stock Information
Friday's Close $10.65
Volume Avg. 360637 shares
Industry Biotechnology and Drugs
Sector Healthcare
Our Stop Loss Members Only
Expected Move Members Only
Optionable? Yes

Stock Financials
Profit Margin .00%
Operating Margin -790.44%
Debt-to-Equity .00%
P/E ttm 0.00
EPS ttm $-1.330
Total Revenue $4,550,000
Market Cap $293,940
Annual Dividend $.00
Yield .000%
ROE 0.00%
Revenue Growth Rate Quarterly 0.00%
Earnings Growth Rate Quarterly 0.00%
Earnings Growth Rate Yearly 0.00%
Multi-Year Average Revenue Growth Rate 166.23%
Multi-Year Average Earnings Growth Rate N/A
Institutional Ownership Members Only
Value Rating Members Only
TurnerTrends Score  (Range: -100 to 210) Members Only


Latest News

Tue, 9 Mar 2010 20:31:31 Etc/GMTVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (EDGAR Online)
Thu, 25 Feb 2010 21:00:00 Etc/GMTVanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S. (PR Newswire)
Thu, 18 Feb 2010 11:50:00 Etc/GMTBiopharma Stock Alert for Vanda Pharmaceuticals Inc. Issued by StockPreacher (GlobeNewswire)
Tue, 16 Feb 2010 21:00:43 Etc/GMTVanda Pharmaceuticals, Inc. Q4 2009 Earnings Call Transcript (at Seeking Alpha)
Tue, 16 Feb 2010 14:30:00 Etc/GMTVanda Pharmaceuticals, Inc. Earnings Call scheduled for 9:30 am ET today (CCBN)
Tue, 16 Feb 2010 14:13:14 Etc/GMTVanda 4Q loss widens on expenses (AP)
Tue, 16 Feb 2010 13:35:02 Etc/GMTUPDATE - Vanda posts wider-than-expected Q4 loss (at Reuters)
Tue, 16 Feb 2010 13:16:20 Etc/GMTLessons from the Best-Performing Stocks (at Seeking Alpha)
Tue, 16 Feb 2010 12:54:57 Etc/GMTVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition (EDGAR Online)
Tue, 16 Feb 2010 12:30:00 Etc/GMTVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results (PR Newswire)
Thu, 11 Feb 2010 21:42:45 Etc/GMTCall-Selling in Vanda Pharma (TheStreet.com)
Tue, 9 Feb 2010 19:09:00 Etc/GMTVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010 (PR Newswire)
Wed, 20 Jan 2010 18:41:50 Etc/GMTThese Stocks Can Easily Double Your Money (at Motley Fool)
Tue, 12 Jan 2010 18:42:05 Etc/GMTCompetitive Schizophrenia Market (Zacks.com)
Mon, 11 Jan 2010 22:15:11 Etc/GMTVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (EDGAR Online)
Mon, 11 Jan 2010 21:06:32 Etc/GMTDrug News: Impotence, Arthritis and Schizophrenia (at The Wall Street Journal Online)
Mon, 11 Jan 2010 17:05:17 Etc/GMTSales start for Vanda Pharmaceuticals schizophrenia treatment (at bizjournals.com)
Mon, 11 Jan 2010 13:16:00 Etc/GMTFanapt(TM) Launches in the U.S. (PR Newswire)
Mon, 4 Jan 2010 14:19:03 Etc/GMTBiotech's 2009 Movers & Shakers: BioBuzz (at TheStreet.com)
Mon, 4 Jan 2010 14:19:03 Etc/GMTBiotech's Movers & Shakers 2009: BioBuzz (at TheStreet.com)
News provided by Yahoo! Finance
Home | Stock Ratings | Top 100 Stocks | New Hot Stock Picks | Sector Analyzer | Industry Analyzer | Member's Area | Articles | FAQ | Contact Us | Terms of Use | Advertise
(C) Copyright TurnerTrends, Inc.  All Rights Reserved.

*Past performance does not guarantee future results. TurnerTrends makes no representations or warrants that just because a stock would have made a profit in the past, using TurnerTrends buy recommendations or sell recommendations, it will make any profits in the future. It is possible that these same stocks will lose money in the future using the TurnerTrends stock recommendations.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither TurnerTrends nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the TurnerTrends site, a user agrees not to redistribute the information found therein.